OmicsBank has raised $2.25 million in seed funding from Redesign Health to expand its clinical data infrastructure across the U.S., Asia and the Middle East.
The San Francisco-based company connects fragmented hospital data for drug development, real-world evidence research and healthcare AI applications. The new funding will support expansion among health systems, pharmaceutical and biotechnology companies, contract research organizations and AI developers.
Founded in 2025 by Sumit Sinha and Vijay Goel, OmicsBank has deployed its technology across more than 90 hospitals and diagnostic laboratories in Asia.
Its network currently includes longitudinal electronic health record data from 12.5 million patients, more than 30 million DICOM medical images, 6 million pathology slides, and approximately 500,000 genome sequences.
OmicsBank targets a major challenge in clinical research and healthcare AI: the underrepresentation of large global populations in datasets used for drug development, biomarker discovery, and model training.
India represents nearly 20% of the world’s population, while South Asian countries collectively account for roughly 25%, but the release cited research indicating these populations make up about 2% or less of participants in large-scale global genomic studies.
OmicsBank’s infrastructure standardizes and de-identifies information within hospital environments and connects clinical events with imaging and multi-omics data.
Pharmaceutical, biotechnology, and AI organizations can use the resulting datasets for disease research, biomarker discovery, treatment-response analysis, and model training and evaluation.
Participating hospitals can also use the infrastructure to search their own clinical archives, identify research cohorts and support prospective studies.
The company already works with pharmaceutical and biotechnology organizations across oncology, neurology, cardiology, nephrology, endocrinology, immunology, and dermatology.
It is also working with frontier AI organizations on pre-training, post-training and reinforcement learning for clinical and multimodal models.
In the U.S., OmicsBank is pursuing a two-sided strategy. It plans to give drug developers, CROs and AI companies access to research-ready data from Asia while partnering with U.S. health systems to add more populations to its standardized longitudinal network.
The company will also use the funding to expand its hospital footprint across the Middle East and Southeast Asia and develop GPU-enabled research environments for AI model training, reinforcement learning, biomarker discovery, real-world evidence and computational biology.
OmicsBank’s offering spans FHIR and OMOP CDM-structured EHR data along with imaging, genomic, transcriptomic, proteomic, phenomic and metabolomic datasets and biospecimens. The company said its process operates under IRB and ethics committee approvals and is ISO 27001-certified and HIPAA- and GDPR-compliant.
KEY QUOTES:
“Drug development and healthcare AI are becoming increasingly sophisticated, but the data powering them still represents a relatively narrow slice of the world. We’ve built the infrastructure to make rich clinical and biological data from Asia and other underrepresented populations available for research, ethically and at scale, while remaining compliant with local and international laws.”
Sumit Sinha, Co-Founder And CEO Of OmicsBank
“They saw early that the lack of well-structured, representative clinical data was becoming a constraint on drug development and research, and they moved quickly to do something about it.”
Neil Patel, Head Of Ventures At Redesign Health
“Making medical and pharmaceutical research more representative of emerging-market populations is not only a matter of inclusion. People underrepresented in medical research make up the majority of the world’s population.”
Oscar Ramos Moreno, Managing General Partner At Orbit Ventures
